How are Drug Makers Getting Defective Drugs on the Market?

If you want to believe all the good press about a new prescription drug, then you should believe the negative press as well. However, many drug companies do not want you to see any negative press about their new prescription drugs. To that end, some drug makers utilize less-than-honest methods to flood the market with positive reports about their drugs.

In one instance, a subsidiary of Pfizer promoted its drugs by having a ghostwriter draft a favorable report. The company then hired an academic author to attach his name to the article so that a medical journal would publish it. Not only are practices like this dishonest, but the drug makers also tend to fail to disclose deadly risks and side effects associated with their drugs. Bayer failed to disclose the link between its drug, Yaz, and blood clots and strokes. As a result, thousands of women suffered injuries and reportedly one confirmed death linked to Yaz.

If a drug company funds a study, it is more likely that the researchers will report the results in a favorable light. Since pharmaceutical companies pay for the majority of studies conducted on their drugs, these studies may tend to show drugs, even defective drugs, in a more positive light. The alarming fact about all of this is that these defective drugs still slip past FDA regulations and make their way onto the mainstream consumer marketplace.

Are you concerned about a harmful drug and your health?

Leave a Reply

Your email address will not be published. Required fields are marked *